Rituximab in the Treatment of Thyroid Eye Disease: A Review.
作者： Rochella A. Ostrowski , Melissa R. Bussey , Yasmin Shayesteh , Walter M. Jay
DOI: 10.3109/01658107.2015.1039140
关键词:
摘要: Graves disease is an autoimmune thyroid classically characterised by a clinical triad consisting of hyperthyroidism, diffuse goitre, and eye disease. Thyroid immunologically mediated condition in which humoral immunity thought to play central role. traditionally treated with high-dose glucocorticosteroids surgical orbital decompression. However, responses are inadequate alternative treatment options needed. Rituximab, anti-CD20 monoclonal antibody, shows promise as novel therapeutic option for There 43 cases rituximab the medical literature, larger studies warranted determine long-term effectiveness rituximab. Rituximab may represent attractive new disease, especially case that refractory current strategies.
sci-hub.se 参考文章(37)
Kostas G. Boboridis, Gerasimos E. Krassas, Aliki Stafilidou, Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids Clinical Endocrinology. ,vol. 72, pp. 853- 855 ,(2009) , 10.1111/J.1365-2265.2009.03762.X
G. Vannucchi, I. Campi, M. Bonomi, D. Covelli, D. Dazzi, N. Currò, S. Simonetta, P. Bonara, L. Persani, C. Guastella, J. Wall, P. Beck-Peccoz, M. Salvi, Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology. ,vol. 161, pp. 436- 443 ,(2010) , 10.1111/J.1365-2249.2010.04191.X
H. C. Hasselbalch, P. Junker, C. H. Nielsen, L. Hegedüs, D. El Fassi, D. El Fassi, D. El Fassi, Systemic adverse events following rituximab therapy in patients with Graves’ disease Journal of Endocrinological Investigation. ,vol. 34, ,(2010) , 10.3275/7411
Deirdre Cocks Eschler, Alia Hasham, Yaron Tomer, Cutting edge: the etiology of autoimmune thyroid diseases Clinical Reviews in Allergy & Immunology. ,vol. 41, pp. 190- 197 ,(2011) , 10.1007/S12016-010-8245-8
G. M. Lehmann, T. M. Garcia-Bates, T. J. Smith, S. E. Feldon, R. P. Phipps, Regulation of Lymphocyte Function by PPARγ: Relevance to Thyroid Eye Disease-Related Inflammation Ppar Research. ,vol. 2008, pp. 895901- 895901 ,(2008) , 10.1155/2008/895901
D. E. Fassi, C. H. Nielsen, J. Kjeldsen, O. Clemmensen, L. Hegedus, Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease Gut. ,vol. 57, pp. 714- 715 ,(2008) , 10.1136/GUT.2007.138305
L. Saranac, S. Zivanovic, B. Bjelakovic, H. Stamenkovic, M. Novak, B. Kamenov, Why is the thyroid so prone to autoimmune disease Hormone Research in Paediatrics. ,vol. 75, pp. 157- 165 ,(2011) , 10.1159/000324442
Sara Madaschi, Alessandro Rossini, Ilaria Formenti, Vito Lampasona, Stefania Bianchi Marzoli, Gabriella Cammarata, Letterio S Politi, Vittorio Martinelli, Elena Bazzigaluppi, Marina Scavini, Emanuele Bosi, Roberto Lanzi, Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review. Endocrine Practice. ,vol. 16, pp. 677- 685 ,(2010) , 10.4158/EP09385.RA
R S Bahn, Autoimmunity and Graves Disease Clinical Pharmacology & Therapeutics. ,vol. 91, pp. 577- 579 ,(2012) , 10.1038/CLPT.2012.10
Daniel El Fassi, Claus H. Nielsen, Steen J. Bonnema, Hans C. Hasselbalch, Laszlo Hegedüs, B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves’ Disease: A Controlled Pilot Study The Journal of Clinical Endocrinology and Metabolism. ,vol. 92, pp. 1769- 1772 ,(2007) , 10.1210/JC.2006-2388